differential oestrogen receptor binding associated clinical outcome breast cancer 
oestrogen receptor-alpha er defining driving transcription factor majority breast cancers target genes dictate cell growth endocrine response yet genomic understanding er function restricted model systems1- map genome-wide er-binding events chromatin immunoprecipitation followed high-throughput sequencing chip-seq primary breast cancers patients different clinical outcomes distant er-positive metastases find drug-resistant cancers still recruit er chromatin er binding dynamic process acquisition unique er-binding regions tumours patients likely relapse acquired er regulatory regions associated poor clinical outcome observed primary tumours reveal gene signatures predict clinical outcome er-positive disease exclusively find differential er-binding programme observed tumours patients poor outcome due selection rare subpopulation cells due foxa1-mediated reprogramming er binding rapid time-scale parallel redistribution er foxa1 binding events drug-resistant cellular contexts supported histological co-expression er foxa1 metastatic samples establishing transcription-factor mapping primary tumour material show plasticity er-binding capacity distinct combinations cis-regulatory elements linked different clinical outcomes 
